3 Hard Facts Moderna and Pfizer Investors Need to Know About the Omicron Variant

As the leading coronavirus vaccine makers in the U.S., Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) will once again be put to the test by a new viral variant. Bancel's opinion isn't the only thing that investors need to be aware of when it comes to the new variant, though. In particular, there are three facts that will influence how Pfizer and Moderna's stocks perform in light of omicron -- and they aren't all pretty.